NCT07189195View on ClinicalTrials.gov

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 15, 2029

Study Completion Date

December 15, 2030

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaRefractory Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Malignant Solid NeoplasmUnresectable Pancreatic Adenocarcinoma
Interventions
DRUG

TR-002

Weekly intravenous infusion

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER